A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms

The toll-like receptor 9 (TLR9) agonists CpG oligodeoxynucleotides (CpG ODNs) have been recognized as promising adjuvants for vaccines against infectious diseases and cancer. However, the role of TLR9 signaling in the regulation of antigen uptake and presentation is not well understood. Therefore, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Ying-Chyi, Liu, Shih-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517169/
https://www.ncbi.nlm.nih.gov/pubmed/26215533
http://dx.doi.org/10.1038/srep12578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517169/
https://www.ncbi.nlm.nih.gov/pubmed/26215533
http://dx.doi.org/10.1038/srep12578

Ejemplares similares